门静脉期腹部CT对比剂注射方案:固定注射时长是否较固定注射流率改善肝脏强化
固定时长组的平均肝脏强化及按碘剂量归一化的平均肝脏强化均显著高于固定流率组,但两组强化指标的个体间方差无显著差异。
要点
- 固定注射时长组平均肝脏强化50.0±12 HU高于固定流率组54.8±11 HU(原文如此),组间差异有统计学意义。
- 固定注射时长组MHE/I为1.53±0.43 HU/g,固定流率组为1.66±0.51 HU/g(原文如此),组间差异有统计学意义。
- 两组间MHE方差(p=0.51)与MHE/I方差(p=0.08)均无显著差异,个体间变异未见明显不同。
核心结论
- 固定对比剂注射时长较固定注射流率可获得更高幅度的肝脏强化指标。
- 两种注射方案间肝脏强化指标的个体间变异无显著差异。
研究设计与样本
- 研究纳入接受门静脉期腹部CT的门诊患者,固定时长组于2018年2月至11月检查,固定流率组于2020年1月至7月检查。
- 固定时长组56例女性、60例男性,注射时长35秒;固定流率组66例女性、62例男性,注射流率3 mL/s。
- 所有患者按1.22 mL/kg注射碘海醇350,排除患有肝脏、肾脏或心脏疾病者。
- 肝脏强化测量采用平扫与增强图像上的感兴趣区,比较平均肝脏强化(MHE)及按碘剂量归一化的平均肝脏强化(MHE/I),采用非配对t检验与F检验。
关键影像表现/征象
- 两组年龄、体重、体质指数及对比剂剂量无统计学显著差异(p>0.05)。
诊断标准与关键数值
- 固定注射时长组MHE为50.0±12 HU,固定流率组为54.8±11 HU(原文如此),p=0.001。
- 固定注射时长组MHE/I为1.53±0.43 HU/g,固定流率组为1.66±0.51 HU/g(原文如此),p=0.04。
- MHE方差比较p=0.51,MHE/I方差比较p=0.08,均无显著差异。
临床应用与阅片要点
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: To assess whether a fixed contrast media (CM) injection duration improves the magnitude and inter-patient variability in hepatic enhancement over a fixed injection rate.
METHODS: Outpatients who underwent portovenous phase abdominal CT (fixed duration, February-November 2018; fixed rate, January-July 2020) with 1.22 mL/kg iohexol 350 were included. Subjects with liver, kidney or heart disease were excluded. The number of subjects and injection protocols were as follows: fixed duration arm, 56 women, 60 men, 35 s injection duration; fixed rate arm, 66 women, 62 men, 3 mL/s injection rate. Liver attenuation measurements were obtained from regions of interest on pre- and post-contrast images. Mean hepatic enhancement (MHE) and MHE normalized to iodine dose (MHE/I) were compared (unpaired t-tests and F-tests).
RESULTS: There was no statistically significant difference in age, weight, body mass index or CM dosing (p > 0.05). Enhancement indices were significantly lower in the fixed rate group as compared to the fixed duration group, as follows: MHE, 50.0 ± 12 vs. 54.8 ± 11 HU (p = 0.001); and MHE/I, 1.53 ± 0.43 vs. 1.66 ± 0.51 HU/g, (p = 0.04). However, there was no significant difference in the variances of MHE (p = 0.51) and MHE/I (p = 0.08).
CONCLUSION: A fixed CM injection duration yields a greater magnitude in hepatic enhancement indices than a fixed injection rate. Inter-patient variability in hepatic enhancement indices do not significantly differ between the two injection protocols.
引用
- Costa AF, Peet K. Contrast media injection protocol for portovenous phase abdominal CT: does a fixed injection duration improve hepatic enhancement over a fixed injection rate? Abdom Radiol (NY). 2021. PMID: 33386915. doi:10.1007/s00261-020-02919-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。